1 Bayer HealthCare Germany, Market Access, Leverkusen, Germany 2 Bayer HealthCare Pharmaceuticals, Global HEOR, Whippany, USA 3 IMS Health, RWES, London, United Kingdom Background: Regorafenib was approved by the EMA in June 2014 for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) in patients who progressed on or are intolerant to prior treatment with imatinib and sunitinib. 1 Hopital Beaujon, ´ ˆ Oncologie medicale, Clichy, France 2 Hopital de la Timone, Oncologie 3 ´ ´ ˆ digestive et hepato-gastro-ent erologie, Marseille, France Hopital ´ ´ Saint-Antoine, Hepato-gastro-ent erologie, Paris, France 4 Institut Gustave ´ ´ ˆ Roussy, Gastro-enterologie et hepatologie, Villejuif, France 5 Hopital Jean Mermoz, Gastro-Entero-Hepatologie, Lyon, France 6 GERCOR Lab, Translational Research, Levallois-Perret, France 7 Centre Hospitalier ´ ´ Universitaire Vaudois, Centre de Therapies Experimentales, Lausanne, ˆ ˆ Switzerland 8 Hopital Beaujon, Radiologie, Clichy, France 9 Hopital 10 ´ Beaujon, Hepatologie, Clichy, France Centre Hospitalier Universitaire 11 ´ ˆ Vaudois, Oncologie medicale, Lausanne, Switzerland Hopital Necker, ´ Pharmacie, Paris, France 12 GERCOR, Operations cliniques, Paris, France 13 ´ Institut Franco-Britannique, Oncologie medicale, Levallois-Perret, France
HOPITAL JEAN MERMOZ LYON RADIOLOGIE TRIAL
No conflict of interest.Ģ352 POSTER Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma: Final results of the SUN-CK phase II trial from GERCOR IRCĢ351 POSTER Cost-effectiveness analysis of regorafenib for gastrointestinal stromal tumour (GIST) in GermanyĬ.
Oxaliplatin based regimens can be effective in the second line treatment of metastatic gastric cancer patients.
0 kommentar(er)
